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AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Miniperspective
Samuel H. Myers, Valerie G. Brunton, and Asier Unciti-Broceta*
Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road
South, Edinburgh EH4 2XR, U.K.
ABSTRACT: Dysregulation of the AXL receptor tyrosine kinase
has been associated with many types of cancer. It has not been
until recently, however, that targeting AXL has come under the
spotlight because of ever accumulating evidence of its strong
correlation with poor prognosis and drug resistance. The entry of
the ﬁrst AXL-branded inhibitor in clinical trials in 2013 marked
an important milestone for the clinical validation of AXL as an
anticancer target. Nevertheless, to weigh the current contribution
and potential future impact of AXL inhibition in the clinic, it is
fundamental to recognize that several kinase inhibitors approved
or in clinical development have AXL as either a prominent
secondary or even the primary target. Through this review, the
chemical and biological properties of the main inhibitors targeting
AXL (either intentionally or unintentionally) will be discussed,
along with the prospects and challenges to translate AXL inhibitors into a bona ﬁde therapeutic option.
1. INTRODUCTION
Receptor tyrosine kinases (RTKs) are multidomain trans-
membrane proteins that function as sensors for extracellular
ligands. Ligand receptor binding induces receptor dimerization
and activation of their intracellular kinase domain, leading to
the recruitment, phosphorylation, and activation of multiple
downstream signaling cascades.1 To date, 58 RTKs have been
identiﬁed in the human genome, which regulate a broad range
of cellular processes, including cell survival, growth, diﬀer-
entiation, proliferation, adhesion, and motility.1,2
In 1991 Bryan and co-workers were the ﬁrst to report the
discovery of an unidentiﬁed transforming gene, eventually
named AXL, from two patients with chronic myeloid leukemia
(CML).3 The AXL protein (also known as UFO, ARK, and
TYRO7) was later classiﬁed as a RTK belonging to the TAM
(TYRO3, AXL, and MER) subfamily. Since then, over-
expression or overactivation of the AXL protein has been
correlated with the promotion of multiple tumorigenic
processes. High levels of AXL expression have been associated
with poor prognosis in diﬀerent cancers such as glioblastoma
multiforme,4 breast5 and lung6 cancer, osteosarcoma,7 and
acute myeloid leukemia.8 In addition, it has been demonstrated
that abnormal activation of AXL signaling is one prominent
mechanism by which tumor cells undergo epithelial−mesen-
chymal transition (EMT)9,10 and develop drug resistance to
both targeted therapies10−12 and chemotherapy.13,14 EMT is a
process consisting of multiple biochemical changes by which
polarized epithelial cells gain a mesenchymal cell phenotype,
leading to increased migration and invasive properties. In
cancer, EMT biomarkers are a hallmark of invading cells and
consequently cancer metastases.9,10 Accumulating evidence
supporting the role of AXL in cancer together with the ﬁrst
entry of a selective AXL inhibitor in clinical trials15 has brought
AXL inhibitors to the center of pharma interests. As some
excellent articles have recently reviewed the biological role of
AXL in cancer,16−19 the aim of this review is to complement
them by focusing on the most signiﬁcant medicinal chemistry
developments and challenges found on the pharmacological
targeting of AXL kinase activity with small molecules.
2. THE AXL/GAS6 AXIS
2.1. Structure of AXL and Its Major Ligand GAS6.
Proteins within the TAM family contain a β-stranded N
terminal lobe consisting of two immunoglobulin (Ig) like
domains and two ﬁbronectin type III (FTIII) repeats which
comprise the extracellular region. This is connected via a
transmembrane region to a helical C terminal lobe that contains
an intracellular kinase domain19 (Figure 1a). TAM family
members TYRO3 (aka BRT, DTK, RSE, SKY, and TIF) and
MER (aka MERTK, RP38, and TYRO12) can bind to two
vitamin K-dependent extracellular ligands, protein S and the
growth arrest speciﬁc protein 6 (GAS6). Of these two ligands,
AXL has been shown to bind only GAS6, a secreted protein of
75 kDa (Figure 1a).19 The aﬃnity of TAM proteins for the
ligand GAS6 is diﬀerent, following the ranking of aﬃnity AXL >
TYRO3 > MER. AXL possesses around 10-fold superior aﬃnity
for GAS6 than MER.17 Apart from protein S and GAS6,
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additional extracellular ligands for TAM receptors have been
recently discovered such as TUBBY, TULP-1, and galectin-
3,20,21 while evidence so far suggest that AXL can only be
activated by GAS6 and TULP-1.20
2.2. Receptor Activation and Downstream Signaling.
AXL can be activated by a variety of mechanisms (Figure 1b),
the most common being the ligand dependent activation in
which AXL binds with GAS6 to form a dimer complex
consisting of two AXL molecules bound to two GAS6
molecules. Other activation mechanisms can occur such as
ligand independent activation,22 which tends to happen when
AXL is greatly overexpressed or under oxidative stress, e.g.,
ligand independent AXL activation in vascular smooth muscle
cells.23 Heterophilic activation of AXL with either TYRO3 or
MER has been hypothesized. While there is no evidence yet of
AXL/MER interactions,24 it has been recently shown that AXL
and TYRO3 heterodimerize or coexist in the same molecular
complex in chronic lymphocytic leukemia B-cells.25 GAS6-
independent heterophilic dimerization with non-TAM kinases
such as VEGFR1 has also been observed,26 which represents an
alternative resistance mechanism developed in response to anti-
VEGFR1 therapy. Lastly, transcellular homophilic binding of
the extracellular domains of AXL has been proven, where the
extracellular binding of the AXL protein causes cell aggregates
leading to increased AXL kinase activity.27 Under physiological
conditions, maximal stimulation of TAM RTKs including AXL
is achieved in the presence of the speciﬁc protein ligand and an
extracellular lipid moiety, the lipid phosphatidylserine (PtdSer).
While PtdSer is an abundant phospholipid ubiquitously present
in the membrane of all cells, it is mostly found in the inner
layer, pointing its polar head toward the cytoplasm, due to the
action of a class of enzymes called ﬂippases.28 PtdSer becomes
available to activate TAM receptors only when externalized on
the cell membranes in apoptotic cells, aggregating platelets,
exosomes and invading virus envelopes.19
Dimer formation promotes autophosphorylation of tyrosine
residues on the intracellular region of AXL, most prominently
on Y779, Y821, and Y866.19 The phosphorylated kinase
domain then activates downstream proteins by cross-
phosphorylation, and various signaling cascades take place.
The main signaling pathways activated by the GAS6/AXL axis
are shown in Figure 1c. AXL activation causes phosphorylation
of GRB2, which subsequently activates the RAS-RAF-MEK-
ERK pathway leading to cancer cell proliferation.29 AXL also
phosphorylates PI3K, thus leading to increased levels of
phosphatidylinositol trisphosphate and resulting in recruitment
and activation of AKT. AKT is then responsible for the
activation of multiple prosurvival proteins, such as IKK,
MDM2, or mTOR, and the inactivation of proapoptotic signals
such as the BCL-2 family member BAD. Direct AXL-mediated
phosphorylation of SRC or through crosstalk with other RTK
and the subsequent activation of FAK leads to the promotion of
migration and invasiveness.19 As mentioned, apart from
downstream pathways, AXL has also been shown to exhibit
crosstalk with numerous RTK such as VEGFR,26 EGFR,30 and
MET,31 which highlights the complexity of the regulatory role
of the AXL receptor and underlines the plausible involvement
of AXL in diﬀerent mechanisms of drug resistance observed in
some cancers. In addition, AXL and other TAM proteins play a
signiﬁcant role in inﬂammatory processes;19 this is due to the
phosphorylation of AXL causing the upregulation of SOCS
proteins and STAT-1.32 The importance and implications of
the TAM family in inﬂammatory events and disease will be
further discussed in the last section of this review.
2.3. AXL in Cancer. Overexpressed levels of AXL have been
found in numerous cancer types and in most cases high AXL
expression correlates with a poorer patient prognosis. AXL gene
expression is mediated by SP1/SP3 transcription factors and
modulated by CpG methylation of its promoter.33 In addition,
the expression of the AXL receptor is post-transcriptionally
regulated by two speciﬁc microRNAs, miR-34a and miR-199a/
b, the expression of which is suppressed by promoter
methylation in several solid tumors (e.g., non-small-cell lung
cancer (NSCLC), colorectal cancer, breast cancer).34
In NSCLC, interest in AXL as a potential oncology target has
risen in recent years due to the involvement of AXL
upregulation in resistance to EGFR-targeted therapy10 along
with evidence of AXL crosstalk with EGFR.30 EGFR-driven
Figure 1. (a) AXL kinase and its extracellular ligand GAS6. (b) Types of AXL activation: (1) GAS6 ligand-dependent activation of AXL; (2) ligand
independent activation of AXL; (3) heterophilic activation of AXL with a non-TAM family protein; (4) heterophilic activation of AXL with MER or
TYRO3; (5) transcellular ligand independent activation of AXL. (c) Downstream AXL signaling pathways upon classical GAS6-mediated activation.
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tumors are typically treated with erlotinib (structure not
disclosed), a potent EGFR inhibitor; however, these tumors can
develop resistance with one major cause of this thought to be
associated with AXL overexpression.35 It has been demon-
strated that continuous EGFR inhibition ultimately induces
GAS6 upregulation, hence causing increased AXL activity.
These data are further supported by increased levels of AXL,
GAS6, and protein S being found in over 50% of NSCLC cell
lines, with AXL and MER being the most phosphorylated
RTKs in NSCLC cells.36 AXL upregulation tends to correlate
with lymph node metastasis and poorer patient survival.37 In
vitro knockdown studies have shown that inhibition of AXL
causes a decrease in the growth of NSCLC cells and a
signiﬁcant reduction of migration and invasiveness.38
AXL is generally expressed at low concentrations in healthy
breast tissue, while in the advanced stages of breast cancer
levels of AXL expression are signiﬁcantly increased, particularly
in ER+ cells,39 and correlate with a highly invasive phenotype.40
In breast cancers, overactivation of AXL signaling is further
enhanced by the progesterone receptor B through upregulation
of GAS6 and it has been reported that HER2 can also activate
AXL signaling.41 Lorens and co-workers showed that RNAi
knockdown of AXL in triple negative breast cancer models
reduces tumor growth and metastases in mice.42 Other studies
have also shown the importance of AXL inhibition in breast
cancer cell migration.43 The pathological role of AXL in breast
cancer is also evidenced by its association with resistance to
lapatinib (structure not disclosed) in HER2+ breast cancer.44
Table 1. Summary of the Main AXL Inhibitors and Their Target Kinases





IC50 (in vitro) = 11 nM
51 GSK Phase II, active, not recruiting
IC50 (in cells) < 100 nM
44
2 Cabozantinib (XL184, BMS-





IC50 (in vitro) = 7 nM
57 Exelixis Inc./various, including
NCI and Memorial Sloan
Kettering Cancer Center
Approved for medullary thyroid cancer
IC50 (in cells) = 42 nM
57 Phase II and III for diﬀerent solid
tumors




IC50 (in vitro) = 11 nM
59 Eli Lilly and Co. Phase I, active, recruiting
IC50 (in cells) = 2 nM
59
4 MGCD265 MET, AXL,
VEGFR2,
Data for AXL not reported Mirati Therapeutics Phase I, active, recruiting




IC50 (in vitro) = 1.1 nM
52 Bristol-Myers Squibb/Aslan
Pharmaceuticals
Phase I, active, not recruiting





IC50 (in vitro) = 10 nM
61 NeoPharm Preclinical
IC50 (in cells) < 0.5 μM
61
7 LDC1267 MET, AXL,
TYRO3
IC50 (in cells) = 19 nM
62 Lead Discovery Centre Preclinical






IC50 (in vitro) = 0.56 μM
66 Pﬁzer Approved for CML with resistance to
treatment
IC50 (in cells) = 0.34−1.65 μM
66 Phase II and III for diﬀerent CML
stages
9 Gilteritinib (ASP2215) FLT3 and mu-
tants, ALK,
AXL
IC50 (in vitro) < 1 nM
68 Astellas Pharma Global Phase I/II, active, recruiting
10 SGI-7079 MET, MER,
YES, RET,
FLT3, AXL




IC50 (in cells) < 1 μM
70




IC50 (in vitro) = 27 nM
71 Huntsman Cancer Institute/
Tolero Pharmaceuticals
Preclinical






IC50 (in vitro) = 294 nM
72 Pﬁzer/Further clinical sponsors
include NCI, EORTC, etc.
Approved for NSCLC
Phase II/III for diﬀerent solid tumors
13 Amuvatinib (MP470) KIT, PDGFR1,
FLT3, RET,
AXL
IC50 (in cells) < 1 μM
79 Astex Pharmaceuticals Phase II, development discontinued
14 UNC2025 MER, FLT3,
AXL, TYRO3
IC50 (in vitro) = 1.6 nM
82 University of North Carolina Preclinical
15 S49076 MET and mu-
tants, AXL,
MER, FGFRs
IC50 (in vitro) = 7 nM
85 Institut de Recherches Interna-
tionales Servier
Phase I, active, recruiting
IC50 (in cells) = 56 nM
85






IC50 (in vitro) = 9 nM
87 Pﬁzer/Further clinical sponsors
include NCI, Baylor Breast
Care Center, M.D. Anderson
Cancer Center, etc.
Approved for renal cell carcinoma,
imatinib-resistant gastrointestinal
stromal tumor, and metastatic pan-
creatic neuroendocrine tumors
Phase II/III for diﬀerent solid tumors
17 BGB324 (R428) AXL (selective) IC50 (in vitro) = 14 nM
53 Rigel Pharmaceuticals/BerGen
BIO
Phase I/II, active, recruiting
IC50 (in cells) < 30 nM
53
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.5b01273
J. Med. Chem. XXXX, XXX, XXX−XXX
C
Several studies have found high levels of phosphorylated
AXL and GAS6 in many glioblastoma cell lines, which are
biomarkers that generally correlate with poorer prognosis and
cancer recurrence.3 In vivo studies have shown that tumor
growth is signiﬁcantly reduced in tumors that have AXL
inhibited, showing a less invasive phenotype with an increased
overall survival of the animals.45 Keating et al. also found that
AXL mRNA levels and protein expression are elevated in
astrocytic patient samples and cell lines.46 RNAi-mediated
silencing of AXL RTK expression led to a signiﬁcant increase in
chemosensitivity of astrocytic cells (including glioblastoma
cells) in response to temozolomide, carboplatin, and vincristine
treatment (structures not disclosed), suggesting scope for
combination therapy with a variety of traditional cytotoxic
agents.46
In prostate cancer there has been shown to be a direct
correlation between the malignancy of the disease and GAS6/
AXL expression in undiﬀerentiated metastatic human prostatic
cancer cells, which leads to activation of AKT and MAPK
phosphorylation.47
Originally discovered in AML (acute myeloid leukemia),
AXL has therefore been long proposed as a therapeutic target
for this disease. AML cells induce secretion of GAS6 by bone
marrow−derived stromal cells which then activates AXL,
stimulating cell survival and drug resistance.48 It has been
shown that inhibition of AXL in AML results in the
improvement of clinically relevant indicators, suggesting AXL
inhibitors could be used on their own or in combination
therapy to treat AML.
3. AXL INHIBITORS
While a wide range of kinase inhibitors that target the AXL
RTK have been described in the literature (see list in Table 1),
in most cases AXL was not the intended primary target but a
secondary consequence of the similarities among the kinase
domains of AXL and other RTK such as MET or MER.
Consequently, many of those inhibitors often exhibit less
potency for AXL than against its main target. Inhibitors falling
into this category are cabozantinib (2)49 and bosutinib (8),50
drugs approved by the FDA for the treatment of medullary
thyroid cancer and CML, respectively, or the drug candidate
foretinib (1).51 Interestingly, the opposite case has also been
described, e.g., the MET-branded inhibitor BMS-777607 (5),52
the potency of which is 3-fold greater against AXL than against
MET in vitro. The ﬁrst inhibitor reported to be purposely
developed as an AXL selective inhibitor was BGB324 (17),53
which also holds the questionable honor of being considered
the ﬁrst AXL inhibitor to enter clinical trials.15
It is important to note that much of the kinase inhibition data
available in the literature were generated in vitro using the
corresponding recombinant proteins. While cell-free assays
provide a practical screening tool for in-house drug discovery
programs, reported biochemical data need to be used with
caution due to the lack of correlation with cell activity.
Consequently, inhibitory activity in cells (rather than
biochemical data) represents the optimal data source to directly
compare the potency of diﬀerent inhibitors. Unfortunately, the
activity of kinase inhibitors in cells is not always reported.
Biochemical and cell activity data (when available) of the main
AXL inhibitors reported to date are compiled in Table 1.
Since the discovery of allosteric AXL inhibitors has not yet
been reported, all kinase inhibitors described in this review are
ATP-competitive inhibitors having either type I or type II
binding modes. Type I inhibitors bind to the ATP site of the
kinase in its active conformation (aspartate−phenylalanine−
glycine (DFG) motif oriented toward the active site or DFG-
Figure 2. Structures of type II kinase inhibitors in clinical and preclinical development that target the AXL RTK.49,51,52,59−62 The hinge-binding
heterocycles are displayed at the left side of the structures. The chemically related structural motifs that connect the “head” heterocycle with the
terminal phenyl ring (in red) are highlighted in blue. Note that all compounds but 4 present a ﬂuoro atom at the para position of the terminal phenyl
ring.
Journal of Medicinal Chemistry Perspective
DOI: 10.1021/acs.jmedchem.5b01273
J. Med. Chem. XXXX, XXX, XXX−XXX
D
in), being the most common mode of binding. Both type I and
type II inhibitors typically contain an adenine-mimicking
heterocyclic moiety that binds to the hinge region of the
ATP site. However, type II inhibitors adopt an extended
conformation via interactions with DFG residues of the
activation loop to enter an allosteric region (adjacent to the
ATP binding site) that is only accessible in the inactive DFG-
out conformation of the kinase.54 Therefore, while the complex
formed by type II inhibitors and the inactive conformation of
the kinase impede substrate-enzyme binding (=enzymatic
competition), ATP molecules and type II inhibitors bind to
diﬀerent conformations of the kinase catalytic site. The type II
binding mode is generally attributed to provide inhibitors that
display superior selectivity proﬁle. However, such a general
assumption has been disputed by some authors.54
3.1. Type II Kinase Inhibitors. Compound 1 is a MET/
VEGFR2 inhibitor (IC50 = 0.4 and 0.9 nM in cell-free assays,
respectively) in clinical development (Figure 2). Cocrystalliza-
tion of 1 with the MET kinase domain shows that the inhibitor
occupies both the ATP binding site and an adjacent pocket of
the inactive conformation of the kinase.55 After validation of its
safety in healthy volunteers during phase I,51 1 went on to stage
II clinical trials for lung, papillary renal carcinoma, hepatocel-
lular carcinoma, and refractory gastric cancer. All trials but one
have now been completed.56 No phase III trials have yet been
initiated. While the anticancer properties of compound 1 are
attributed to MET and VEGFR2 inhibition, 1 inhibits other
kinases such as AXL at the low nanomolar level (IC50 = 11 nM
in cell free assay).51 Inhibitor 1 has been reported to lead to
almost complete inhibition of AXL phosphorylation in
lapatinib-resistance breast cancer cells at 100 nM and to
restore sensitivity to lapatinib (structure not disclosed) in
treated cells.44
2 is an extremely potent VEGFR2 inhibitor (IC50 = 0.035
nM, in cell-free assays) that also inhibits a wide number of
kinases, including MET, KIT, RET, and AXL, in the low
nanomolar range.57 In 2012 the FDA gave approval for its use
in medullary thyroid cancer with orphan drug status.49 A
number of clinical trials sponsored by diﬀerent parties are
ongoing for a wide variety of indications, including NSCLC and
cancers of prostate, kidney, breast, pancreas, and ovaries.56 This
orally available drug inhibits the kinase activity of human
recombinant MET and AXL with IC50 = 1.3 and 7 nM,
respectively, i.e., 35- to 200-fold lower potency than for its main
target VEGFR2 in biochemical assays. On the basis of the cell-
free inhibition data of 2, this compound could in principle be
considered a selective VEGFR2 inhibitor. In cells, however, 2
inhibits phosphorylation of VEGFR2, MET, and AXL at much
closer concentrations (IC50 values of 1.9, 7.8, and 42 nM,
respectively),57 which delineates the limitations of relying only
on biochemical data to evaluate and rank on- and oﬀ-target
activities. A phase II study (NCT01639508) with inhibitor 2 is
currently ongoing in patients with advanced NSCLC whose
tumors present one of the following gene changes: RET, ROS1,
NTRK fusion or increased MET or AXL activity.56 A
randomized, open-label phase III study of 2 versus everolimus
(structure not disclosed) in patients with advanced renal cell
carcinoma has just been reported (NCT01865747).58 The
study concluded that progression-free survival was longer with
inhibitor 2 than everolimus (structure not disclosed) for
patients that had relapsed after VEGFR-targeted therapy and
highlighted the multitargeting capabilities of the drug as partly
responsible for its excellent response rate.
As shown in Figure 2, the chemical structures of inhibitors 1
and 2 are almost identical. Signiﬁcant structural similarities are
also found in related kinase inhibitors such as LY2801653
(3),59 MGCD265 (4),60 5,52 NPS-1034 (6),61 and LDC1267
(7)62 (see chemical moieties highlighted in blue and red in
Figure 2), which may explain why all these compounds strongly
inhibit a common subset of RTKs, including MET, VEGFR2,
MER, and AXL. Inhibitor 3 is a potent MET inhibitor that
targets several RTKs (MST1R, MER, TYRO3, AXL, etc.) at the
low nanomolar range both in biochemical assays and in cells
(Table 1).59 Eli Lilly and Co. has recently completed phase I
trials for inhibitor 3 in healthy volunteers and is currently
recruiting for a safety study in patients with advanced cancer in
combination with cisplatin, cetuximab, gemcitabine, and
ramucirumab (structures not disclosed).59 The goal of this
phase I study is to ﬁnd the recommended phase II dose of 3
that may be safely given to patients with selected advanced
cancers in combination with chemotherapy and/or immuno-
therapy. Another related drug candidate, 4, a potent inhibitor of
MET, VEGFR-2, and other RTKs (IC50 = 1−10 nM, in
biochemical assays),60 also entered several phase I studies with
healthy volunteers and patients with advanced malignancies
under the sponsorship of Mirati Therapeutics. A trial is active
and recruiting to evaluate the safety of daily doses of the drug in
advanced cancer patients. Preliminary results of this study
reported that a NSCLC patient with AXL gene ampliﬁcation
responded very well (∼50% lesion reduction) after just four
daily doses of 4,63 indicating that certain AXL abnormalities
may be clinically relevant oncogenic drivers in NSCLC.
Figure 3. Cocrystal structure of 5 bound to the inactive conformation of MET kinase domain (left panel)52 and main binding interactions of the
inhibitor (right panel).
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5 is a drug candidate developed by Bristol Myers-Squibb that
strongly inhibits MET, AXL, and MER RTKs. X-ray crystal
structure of 5 complexed with the MET kinase domain shows
that the inhibitor binds at the ATP pocket of the MET kinase
with the activation loop in a DFG-out (inactive) conformation
(see Figure 3).52 The 2-aminopyrimidine core anchors the
inhibitor to the hinge region via two hydrogen bonds, whereas
the central phenyl ring and 2-pyridone group interact by π-
stacking and H-bonding with the phenylalanine and glutamate
residues, respectively, of the DGF motif (Figure 3). Analogous
mode of binding was observed for inhibitors 1 and 3. While 5
was rationally designed to inhibit MET (IC50 = 3.9 nM, in
biochemical assays), its inhibitory potency against AXL is
actually higher (IC50 = 1.1 nM, in biochemical assays),
52
meaning that 5 is the most potent in vitro inhibitor that has the
AXL kinase as its primary target. This compound went through
phase I and II clinical trials for advanced or metastatic solid
tumors. While the results have not yet been reported, Aslan
Pharmaceuticals is now sponsoring a new phase I study in
cancer patients to identify the maximum tolerated dose of 5.56
Besides the above-mentioned drugs and clinical candidates,
two additional structurally related inhibitors targeting AXL have
recently been reported, 661 and 7.62 Both compounds contain
some of the key features found in other previously mentioned
AXL inhibitors, i.e., the central phenyl ring and the terminal p-
ﬂuorophenyl moiety in this case connected through a
carboxamidopyrazole linker (Figure 2), groups that are likely
to be involved in type II binding.64 While these compounds are
still in preclinical development, they have displayed remarkable
activities against chemoresistant cell lines and metastasis.
Compound 6, developed by NeoPharm, shows signiﬁcant
inhibitory activity against multiple RTK including AXL, DDR1,
FLT3, KIT, MEK, MET, ROS1, and TIE1. IC50 against human
recombinant MET and AXL was 48 and 10 nM, respectively.61
6 demonstrated inhibition of AXL signaling in NSCLC cells
with acquired resistance to EGFR-tyrosine kinase inhibitors.
Signiﬁcantly, treatment of these resistant cell lines with 6
restored the sensitivity of the cells to geﬁtinib and erlotinib
(structures not disclosed), resulting in induction of cell death.61
Inhibitor 7 inhibits the three members of the TAM family in
cells at low nanomolar levels. Treatment of wild-type natural
killer (NK) cells with 7 eﬃciently enhanced antimetastatic NK
cell activity in vivo.62
3.2. Type I Kinase Inhibitors. Inhibitor 8 is used in the
clinic for the treatment of adult patients with CML after
resistance or intolerance to prior therapy due to its capacity to
inhibit most imatinib-resistant forms of the BCR-ABL fusion
protein. However, 8 is a promiscuous kinase inhibitor that also
inhibits other proteins such as SRC, ABL, MEK, and BMX with
IC50 = 1−10 nM.
65 Through screening of chemical libraries in
the search for inhibitors of AXL signaling, Zhang et al.
discovered that 8 also inhibits GAS6-mediated tyrosine
phosphorylation of AXL in Hs578T breast cancer cells (IC50
= 0.34 μM, similar levels to those found for SRC inhibition in
the same cell line) and inhibited cell motility and
invasiveness.66 In this respect, the inhibitory properties of
compound 8 can be considered unique, since it targets both
receptor and nonreceptor tyrosine kinases that are dysregulated
in many types of cancer. Studies by Yuan et al.50 have shown
that 8 mediates inhibition of AXL signaling in hepatocellular
carcinoma cells and decreases their invasiveness by suppressing
the expression of the EMT-inducing transcription factor SLUG,
further suggesting that the distinct polypharmacological
properties of 8 may become beneﬁcial in the treatment of
various cancer indications and, in particular, metastasis.
As shown in Figures 2 and 4, the chemical similarities
between the structures of compound 8 and inhibitors 1 and 2
are remarkable. The three inhibitors contain a 6-methoxyquino-
line core with substitutions on the positions C4 and C7 of the
heterocycle. Inhibitor 1 can be considered a hybrid molecule
between 2 and 8, since it has a morpholinopropyloxy group at
the C7 position, like 8, and it shares with 2 the same substituted
ﬂuorophenyloxy motif at the C4 position of the quinoline.
While all three compounds contain a central phenyl group that,
in principle, could π-stack with the Phe of the inactivation loop
of the enzyme, compound 8 lacks the key cyclopropyl-1,1-
Figure 4. Chemical structures of multikinase type I inhibitors 8−11 and cocrystal structure of 8 bound to the active conformation of ABL kinase
(reproduced from Trends in Pharmacological Sciences, Vol. 36, Wu, P.; Nielsen, T. E.; Clausen, M. H. FDA-approved small-molecule kinase inhibitors,
pp 422−439, Copyright 2015, with permission from Elsevier67). Shared chemical motifs are highlighted in blue.
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dicarboxamide linkage and the terminal p-ﬂuorophenyl group
required to access the hydrophobic pocket of the DFG-out
conformation of kinases. According to the cocrystal structure of
8 with the ABL kinase domain (Figure 4),67 compound 8 is a
type I kinase inhibitor. Interestingly, compound 8 shares some
structural similarities with other inhibitors of the AXL RTK,
such as gilteritinib (9),68 SGI-7079 (10),9 and TP-0903 (11)71
(see Figure 4). Although there is not yet any X-ray structural
information or biochemical assay addressing the mode of
binding of 9−11 to AXL or related kinases, based on their
structures they are likely to be type I inhibitors. The diﬀerences
in AXL activity among these compounds could become useful
to initiate novel medicinal chemistry campaigns.
Compound 9 is a highly potent inhibitor of FLT3 (including
mutant forms) and AXL with subnanomolar IC50.
68 The
compound exhibits potent antileukemic activity against AML
with either or both FLT3-ITD and FLT3-D835 mutations.69
Under the sponsorship of Astellas Pharma, 9 is currently
undergoing clinical trials (phase I/II) to assess its safety and
tolerability, including the maximum tolerated dose alone and in
combination with chemotherapy, in subjects with relapsed or
treatment-refractory AML.56
10 is a relatively potent AXL inhibitor (IC50 = 58 nM, in cell-
free assays) in preclinical development that also targets MET,
MER, YES, RET, and FLT3 at a similar concentration range.9
10 inhibits GAS6-stimulated AXL signaling in inﬂammatory
breast cancer cells (IC50 < 1 μM), resulting in decreased cell
proliferation and invasion.70 Byers et al. at the MD Anderson
Cancer Center identiﬁed AXL as a potential therapeutic target
for overcoming EGFR inhibitor resistance associated with the
mesenchymal phenotype and demonstrated that treatment with
inhibitor 10 sensitized lung cancer cells to erlotinib (structure
not disclosed), particularly in an acquired resistance setting.9
11 is an AXL-branded inhibitor developed by Bearss and co-
workers at the Huntsman Cancer Institute71 that is currently
under preclinical development by Tolero Pharmaceuticals. The
compound, which was rationally designed using a homology
model of the AXL active site, inhibits AXL with an IC50 = 27
nM (biochemical assays) but also other kinases such as Aurora
A and B, JAK2, ALK, and ABL at even lower concentrations. In
fact, cell cycle studies have revealed that the inhibitor induced
strong cell cycle arrest by inhibition of Aurora A and B.71
Recent studies have shown that 11 is eﬀective in inducing
apoptosis of B-cell chronic lymphocytic leukemia (CLL) cells
as a single agent at nanomolar concentrations and found a
synergistic eﬀect with BTK inhibitors.25 In the same work they
demonstrated that CLL B-cells not only express constitutively
active AXL but also increased levels of TYRO3, although AXL
was found to be the predominant TAM RTK regulating CLL B-
cell survival.
Crizotinib (12,72 see Figure 5) is a clinically approved orally
bioavailable inhibitor of RTKs including MET, ALK, and AXL
(IC50 = 8, 20, and 294 nM, respectively, in biochemical assays).
Pﬁzer developed this ATP-competitive inhibitor through a
structure-based drug design strategy using the MET kinase
domain for cocrystallization experiments.72 12 potently inhibits
cancer cell growth of cell lines harboring fusion variants and
activating mutations of ALK73 and also exhibits antiangiogenic
properties.74 Clinical studies of 12 in ALK-rearranged NSCLC
rapidly demonstrated signiﬁcant activity and clinical beneﬁt,75,76
which led to its early approval by the FDA in 2011.77 In a
recent phase III clinical study of patients with ALK-rearranged
NSCLC with metastasis in the brain, treatment with 12 was
associated with systemic and intracranial disease control at 12
weeks of therapy.78 However, following this period, acquired
resistance to 12 was commonly observed, leading to the
development of preexisting or new intracranial metastatic
lesions.78 Clinical studies of 12 against several cancers with
ALK rearrangements or mutations including metastatic
NSCLC, anaplastic large cell lymphoma, myoﬁbroblastic
tumor, and neuroblastoma are currently ongoing under
diﬀerent sponsorships.77,55
Amuvatinib (13)79 is a promiscuous type I kinase inhibitor
targeting KIT, PDGFR1, FLT3, RET, and AXL developed by
Figure 5. Structures of type I AXL inhibitors 12−17. Shared chemical motifs between compounds 15 and 16 are highlighted in blue.
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Astex Pharmaceuticals. In MDA-MB-231 cells, it has been
shown that this compound inhibits phosphorylation of AXL at
1 μM.79 Inhibition of AXL using 13 reversed EMT in murine
breast cancer stem cells, reducing self-renewal and restoring
sensitivity to chemotherapy.80 After phase I evaluation in
patients with solid tumors,81 13 entered a phase II clinical trial
in patients with NSCLC in combination with standard of care
chemotherapy (platinum and etoposide, structures not
disclosed). Despite favorable safety and preliminary clinical
activity in the ﬁrst stage of this phase II, Astex Pharmaceuticals
announced discontinuation of its clinical development in 2012.
UNC2025 (14)82 is a promising preclinical candidate
developed by Wang and co-workers at the University of
North Carolina. It is a dual MER/FLT3 type I inhibitor (IC50 <
1 nM, in cell-free assays for both kinases) that blocks AXL
kinase activity with an in vitro IC50 of 1.6 nM.
82 In animal
models, oral administration of 14 resulted in target inhibition in
bone marrow leukemia cells.82 This compound derives from a
previous MER/FLT3 inhibitor, UNC1062 (35,83 see Figure 7),
which was shown to reduce activation of MER-mediated
downstream signaling in melanoma cells, inducing apoptosis in
culture and inhibiting invasion.84 On the basis of the
remarkable capacity of 14 and some of its early derivatives to
target AXL, its development program will be the focus of
further discussions in following sections.
S49076 (15)85 is an ATP-competitive inhibitor of MET,
AXL, MER, and FGFRs (Figure 5) that targets AXL at low
nanomolar levels both in vitro (IC50 = 7 nM) and in cells (IC50
= 56 nM, in murine embryonic ﬁbroblasts engineered to
express human AXL). The molecule was designed using a
structure-based approach in the search for potent and selective
MET inhibitors and its mode of binding inferred by X-ray
resolution of cocrystal complexes of 15 analogs with MET.85 Its
chemical structure closely resembles that of sunitinib (16),86 a
potent multitargeted RTK inhibitor approved for the treatment
of diﬀerent cancer indications that also inhibits AXL at the low
nanomolar range (IC50 = 9 nM).
87 15 displays potent
antiproliferative properties in MET- and FGFR2-dependent
gastric cancer cells and inhibits migration of lung carcinoma
cells. 15 potently inhibits phosphorylation of MET, AXL, and
FGFRs in tumor xenograft models. Combination of inhibitor
15 with bevacizumab (structure not disclosed) in xenograft
models of colorectal cancer resulted in near total suppression of
tumor growth, and remarkably, 15 alone induced arrest of
tumor growth in bevacizumab-resistant tumors. A phase I dose-
escalation study of 15 (oral administration) is currently
undergoing in patients with advanced solid tumors to establish
its safety proﬁle.85
17 was the ﬁrst kinase inhibitor to be intentionally designed
to target the AXL RTK (see Figure 5).53 It inhibits AXL in an
ATP-competitive manner in the low nanomolar range (IC50 =
14 nM) and displays signiﬁcant selectivity (>40-fold) toward
MER and TYRO3 (TAM family members) and other kinases
including ABL and MET,53 thus formally being the only
selective AXL inhibitor reported to date. Hollande et al. showed
that 17 is able to block AXL-dependent events in cells,
including AKT phosphorylation, invasiveness of breast cancer
cells, and the production of proinﬂammatory cytokines. Oral
treatment with 17 in mouse xenograft models demonstrated a
dose-dependent reduction of the EMT transcriptional regulator
SNAIL and extended survival (>35%) in a MDA-MB-231
intracardiac mouse model of breast cancer metastasis.53
Additionally, combination with cisplatin (structure not
disclosed) enhanced reduction of liver micrometastases in a
murine model. Originally developed by Rigel Inc.,53 it was
licensed to BerGen BIO in 2011 which is currently conducting
Figure 6. Development of the ATP-competitive (type II), orally available, dual MET/AXL inhibitor 5.
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two phase I clinical trials,15 one of which received FDA orphan-
drug designation for the treatment of AML. These trials are
aimed at evaluating the safety and tolerability of the drug in
AML and NSCLC patients when administered as a single agent
and in combination with cytarabine and erlotinib (structures
not disclosed), respectively.56
3.3. Discovery of Dual MET/AXL Inhibitor 5. As
discussed above, compound 5 is a MET inhibitor showing 3-
fold greater potency for AXL than for MET in biochemical
assays. The development of this drug candidate, which shares
signiﬁcant similarities with other type II kinase inhibitors such
as 1 or 3 (see Figure 2), was carried out at Bristol Myers-
Squibb. Encouraged by the potent inhibitory properties of
pyrrolo[2,1-f ][1,2,4]triazine-based compounds,88 Schroeder,
Borzilleri, and co-workers utilized this scaﬀold in the search
for MET inhibitors. In silico modeling followed by library
synthesis and in vitro screening led to potent MET inhibitors
with poor pharmacokinetic properties.89 Subsequent inves-
tigations focused on the substitution of the pyrrolotriazine
scaﬀold by a pyrrolopyrimidine, which led to potent MET
inhibitors 18 and 19 (see Figure 6).90 While the malonamide
derivative 19 inhibited the target with superior potency, the N-
acylurea, 18, showed higher antiproliferative activity in a MET-
driven human gastric carcinoma cell line (GTL-16 cells).90 The
substitution of the malonamide group by a conformationally
constrained 3-carboxamido-2-pyridone ring led to a dramatic
increment in MET inhibition and superior antiproliferative
activity in MET-dependent GTL-16 cells.91 2-Pyridone
derivative 2091 also inhibited FLT3 and VEGFR2 at low
nanomolar concentration and demonstrated good in vivo
eﬃcacy in a GLT-16 xenograft model.
The success with the 2-pyridone fragment motivated the
team to explore it on derivatives containing a 2-aminopyridine
scaﬀold instead of the pyrrolopyridine one. N-Acylureas
containing the 2-aminopyridine scaﬀold had previously
demonstrated good inhibitory properties against MET but
also potent inhibition of cytochrome P450 (CYP) isozymes.90
Novel derivative 21,52 which displayed high inhibition of MET
kinase activity, served as a starting point for SAR studies. On
the basis of the X-ray structure of derivative 20,91 it was
hypothesized that substitutions at the C3 position of the
pyridine group could provide access to the ribose pocket of the
ATP binding site. Diﬀerent groups were therefore introduced in
that position aiming to improve potency, solubility, and CYP
inhibition proﬁle. Introduction of an N-methylpiperazinyl-
methyl moiety at C3 provided a soluble derivative (derivative
22,52 Figure 6) with good on-target potency but low activity in
cells. Substitutions by smaller, more rigid groups such as
aminopropargyl, hydroxypropargyl, or unsubstituted propargyl
groups led to a slight increase of MET inhibitory properties and
superior antiproliferative activity in MET-dependent GLT-16
cells. Further optimization of DMPK properties resulted in
inhibitor 5, an orally available type II inhibitor with excellent
half-life that inhibits AXL with an IC50 = 1.1 nM (biochemical
assays).52
3.4. Medicinal Chemistry Campaigns for the Discov-
ery of 14 and Related Compounds. Overexpression of the
MER RTK is strongly associated with acute lymphoblastic
Figure 7. Medicinal chemistry campaigns for the discovery of TAM inhibitor 14 and related compounds by Wang and co-workers.82,83,95−97 MER-
compound 52 cocrystal structure was adapted from Huang et al.94 from Journal of Structural Biology, Elsevier, under the Creative Commons License
Deed.
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leukemia (ALL). While MER is not expressed in normal human
T lymphocytes at any stage of development, it is found
ectopically expressed in over 50% of pediatric T-cell ALL.92
Compound 52 (26,93 Figure 7), a polysubstituted purine
derivative originally developed in Schultz’ lab, is a weak
inhibitor of MER (IC50 = 11.3 μM), the complex of which was
cocrystallized with the MER protein and the structure resolved
by Dhe-Paganon and co-workers.94 This information was used
by Wang and co-workers to create a docking model for MER
inhibition.95 On the basis of this model, they proposed a
trisubstituted pyrazolopyrimidine scaﬀold to search for novel
MER inhibitors (Figure 7). Preliminary SAR studies found that
compounds 27 and 28,95 both containing a 4-aminocyclohexyl-
methyl group in R2, displayed nanomolar activity against MER,
with the trans isomer having 3-fold superior potency than the
cis one. Given the similarities of MER with other members of
the TAM subfamily, compounds were also screened against
AXL and TYRO3. As shown in Figure 7, compounds 27 and 28
displayed slightly lower activity for AXL than for MER.
Exploration of diﬀerent alkylamino groups in the position R3 of
the ring showed that the larger the alkyl group, the higher the
selectivity of the compound for MER. Introduction of the small
methylamino group at R3 generated highly potent AXL
inhibitors such as compound 29,95 the only compound of the
series with higher aﬃnity for AXL than MER. Among the range
of aromatic substituents explored at the R1 position, a 4-
piperazinylphenyl group was found to be optimal for AXL
inhibition (see compounds 29 and 31 in Figure 7).95 The trans
isomers were found to be the most active ones across the
libraries, with the most potent MER inhibitor (compound 31,
IC50 = 0.15 nM, in cell-free assays) possessing a phenyl-
propylamino group in R3. All compounds were found to be
ATP competitive inhibitors. Due to its lower molecular weight,
UNC569 (32,95 with IC50 = 2.9 and 37 nM for MER and AXL,
respectively) was the inhibitor chosen for further PD/PK
analysis, showing inhibition of MER phosphorylation in cells
(IC50 = 141 nM in human pre-B leukemia 697 cells) and good
oral bioavailability (57%).
From this point two distinct medicinal chemistry campaigns
were followed. A new family of potent MER inhibitors was
developed by using a pseudo-ring replacement strategy (Figure
7).96 From the new derivatives generated, compound 3396 was
the most potent against AXL (IC50 = 38 nM in biochemical
assays), while the MER-targeting lead compound of the series,
UNC2250 (34),96 displayed good selectivity and PK proﬁle,
potent inhibition of MER phosphorylation in cells, and
antiproliferative activity in a NSCLC cell line. Following
studies on that scaﬀold led to UNC288197 (structure not
disclosed), a potent highly selective MET inhibitor that
demonstrated inhibition of platelet aggregation in collagen-
stimulated human platelet-rich plasma. In parallel, optimization
studies on the scaﬀold of inhibitor 32 proceeded toward
increasing MER selectivity and DMPK properties (Figure 7).
Studies resulted in the MER inhibitor 35,83 which shows high
Figure 8. Synthesis of the speciﬁc AXL inhibitor 17 from commercial starting materials 36 and 39.98
Figure 9. Chemical scaﬀolds investigated by Holland et al. in the search for speciﬁc AXL inhibitors.98
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selectivity (>75-fold) over other TAM kinases, and the drug
candidate 14,82 a dual MER/FLT3 inhibitor with subnanomo-
lar potency (but low selectivity over AXL and TYRO3) that
displays excellent oral bioavilability (100%) and the capacity to
inhibit MER phosphorylation in vivo in leukemic blasts of
mouse bone marrow.
3.5. Discovery of AXL-Selective Inhibitor 17. As
mentioned before, 17 is the most selective AXL inhibitor
reported to date and the ﬁrst one to progress to clinical trials
based on its AXL inhibitory properties.15 The number of
studies reported in the literature with this drug candidate is
limited to biological studies.12,53,98,99 Apart from the original
patent published by Rigel Inc. in 2010,98 no other chemical
report has yet become public. The patent application is thus the
only source available to shed some light on how 17 was
developed and review the structural requirements for the AXL
inhibition activity of this interesting multicyclic [1,2,4]triazole-
based compound.
As shown in Figure 8, the strategy to prepare inhibitor 17
consists of the generation of the polycyclic synthons 38 and 41
(by ﬁve- and six-step synthetic processes, respectively) from
commercial starting materials, followed by a cyclocondensation
reaction to form the central triazole of 17.98 This relatively
straightforward strategy enabled Holland et al. to replace the
pyrrolidine group on the cycloheptan ring of intermediate 3798
with diﬀerent moieties. SAR analyses showed that an amino
group was required in that position for inhibiting AXL (Figure
9), with dialkylated and cyclic amines providing the highest
AXL inhibition activities.98 When the amino group was masked
as a carbamate, aﬃnity for AXL was signiﬁcantly reduced. It is
also notable that halogens or amino groups functionalized with
large cyclic structures were not well tolerated at that position.
Twenty-six out of 56 compounds based on scaﬀold I exhibited
submicromolar IC50 values, showing the versatile potency of the
scaﬀold. Three derivatives based on scaﬀold II were also
synthesized, while only the one shown in Figure 9 exhibited
AXL inhibition at the submicromolar range.98
After the publication of the highly focused patent application
that describes 17 and derivatives,98 the same team at Rigel
Pharmaceuticals Inc. ﬁled divisional patent applications for new
AXL inhibitors.100,101 The protected structures also contain the
central triazole group representative of this unique class of
compounds, while the chemical variety of substituents used in
each of those patents have been signiﬁcantly expanded. It is
therefore likely to expect that the discovery of novel selective
AXL inhibitors will be reported at some point in the future.
3.6. General Considerations with Regard to the Use of
Current AXL Inhibitors in Cancer Treatment. The interest
of Pharma and the research community in AXL inhibitors as
anticancer agents has dramatically increased over the past 10
years. Given the amount of evidence supporting the role of
AXL in cancer and the increasing number of AXL-targeting
candidates entering clinical trials, it is likely that such interest
will continue to rise in the years to come. After a review of the
state-of-the-art, however, it seems clear that the main barrier
that could potentially block the generation of clinically useful
AXL inhibitors is their selectivity proﬁle. The majority of
inhibitors of AXL kinase activity also inhibit other protein
kinases, preferentially RTKs. This is due to the considerable
similarities among the intracellular kinase domains of RTKs,102
which are very signiﬁcant not only within the members of the
TAM subfamily (TYRO3, AXL, and MER), but also among
other RTKs such as MET, FLT3, RON, and Aurora A/
B.67,71,103,104 Consequently, the discovery of ATP-competitive
kinase inhibitors displaying cross-reactivity for multiple RTKs
has been and will continue to be a widespread phenomenon,
whereas selectivity over other groups of kinases should be
expected.105 Due to the complexity of cancer pathology, a
certain level of promiscuity may actually become an advantage
in cases where inhibiting more than one target can lead to a
synergistic eﬀect for treatment. For instance, this may be one of
the reasons behind the remarkable clinical response mediated
by the VEGFR2/MET/AXL inhibitor 2 in patients with
advanced renal cell carcinoma.58 However, in other cases a poor
selectivity proﬁle will result in the inhibition of kinases that are
essential for physiological functions and, consequently, in
severe side eﬀects.106 This issue may become a challenging one,
since an AXL inhibitor will rarely be employed in the clinic on
its own, and drug combinations usually lead to incremental
adverse eﬀects.
Interestingly, across the list of inhibitors described in this
article (Table 1), something can be concluded: contrary to the
general assumption, type II kinase inhibitors provided no
beneﬁt in terms of selectivity over type I inhibitors. A potential
way to improve the selectivity proﬁle of AXL inhibitors would
be to focus on the development of either allosteric or
irreversible inhibitors.107,108 Nonetheless, the unique properties
of inhibitor 17 proves that ATP-competitive inhibitors with
adequate selectivity proﬁle and AXL potency can certainly be
generated.
Due consideration to the immunoregulatory role of AXL,
MER, and TYRO3 is also essential to understand the
limitations of a potential anti-AXL therapy. Studies by Lu and
Lemke reported that TAM triple knockout mice develop broad-
spectrum autoimmunity and a severe lymphoproliferative
disorder.109 Bosurgi et al. showed that ablation of AXL and
MER signaling in mice favors a tumor-promoting environment
in the colon by increasing production of proinﬂammatory
cytokines and reducing clearance of apoptotic neutrophils in
the intestines.110 On the other hand, the role of TAM receptors
in diminishing the innate immune response makes their
inhibition an attractive mechanism to reverse the immunosup-
pressive tumor microenvironment.62 Furthermore, it has been
demonstrated that tumor-macrophage cross-talk is responsible
for stimulating the macrophage secretion of GAS6 in the tumor
microenvironment, which in turn foster tumor growth by
activation of TAM RTKs, particularly AXL.111 Consequently,
while chronic inhibition of TAM family members, particularly
MER, could eventually result in autoimmune side eﬀects,19,24
the beneﬁt provided by the temporary use of AXL inhibitors for
cancer treatment would considerably overcome the associated
risks. To minimize detrimental autoimmune responses, it may
be particularly useful to generate further AXL inhibitors with
selectivity over the other TAM members MER and TYRO3, the
role of which seems to be more important in immunor-
egulation.19
4. CONCLUSIONS
The shift of the Pharma industry and the medical community
toward personalized cancer medicine and genotype-guided
therapeutic intervention is causing an ever-increasing need for
both single- and multitargeted inhibitors.112 While the number
of treatable patients can signiﬁcantly decrease with the use of
drugs that selectively target proteins involved in speciﬁc cancer
types, the eﬀectiveness and safety of these targeted therapies
can be far greater. However, since cancer survival and
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progression are typically driven in most malignancies by more
than one protein or signaling pathway, the clinical use of
targeted monotherapies normally becomes insuﬃcient to fully
control or eliminate the disease.113 Furthermore, resistance
mechanisms typically arise to both chemotherapeutics and
targeted therapies through mutations or activation of additional
proteins or signaling pathways.114 Due to their pathological and
etiological complexity, pharmacological interventions based on
combination strategies will be essential to eﬀectively treat those
cancers.113,114 However, the shortage of highly selective
targeted agents against many relevant oncotargets is limiting
the development of drug combinations with acceptable safety
proﬁles. As more and more proteins involved in neoplasia and/
or chemoresistance mechanisms are uncovered and their roles
elucidated, the need for targeted inhibitors becomes ever
greater.
The prominent role of AXL in the survival, spread, and
mechanisms of drug resistance in diﬀerent solid and blood
cancers strongly supports the choice of AXL inhibition as an
anticancer strategy, especially for advanced disease.16−19,115
Consequently, various drug candidates targeting AXL are
currently under clinical development, and more are expected to
come. Preliminary clinical evidence in a NSCLC patient with
AXL gene ampliﬁcation receiving treatment with AXL/MET
inhibitor 4 has shown that AXL abnormalities may be clinically
relevant oncogenic drivers in certain forms of NSCLC.63 These
particular cancer types could represent the primary clinical
indication for AXL-targeted monotherapy. However, since
cases where AXL is the main driver of the cancer are rare, AXL
inhibitors would be most beneﬁcial as combination partners.
For example, strong evidence indicates that AXL inhibition
could signiﬁcantly beneﬁt anti-EGFR, anti-HER2, or anti-
VEGFR therapies.26,35,44 AXL inhibitors also have the potential
to impact cancer metastasis, but translating this into clinical
trials is currently problematic. Therefore, at the moment AXL
inhibitors show more promise in the treatment of resistant
disease. AXL upregulation is one prominent mechanism
whereby chemoresistance develops in diﬀerent cancers,13,14
therefore strongly indicating that AXL inhibitors could
synergize in the clinic with standard-of-care chemotherapeutics
such as cisplatin (structure not disclosed). If AXL targeting
drugs with adequate selectivity proﬁle are developed and
synergistic drug combinations established, they could provide
cancer patients with new therapeutic options to ﬁght the latest
and most aggressive forms of cancer.
As reviewed in this article, there are currently just a few drug
candidates that have AXL as its primary target and only one
reported clinical candidate can be considered as a selective AXL
inhibitor. One of the challenges we face for the de novo design
of AXL inhibitors is the lack of crystallographic data for the
kinase domain of the AXL RTK. Given the growing demand for
small molecule inhibitors targeting AXL activity, this limitation
will certainly be addressed in the near future. Nonetheless, until
this information becomes available, ligand-based approaches
provide one useful route to develop AXL inhibitors with
improved properties. This comprehensive review of the state-
of-the-art is an eﬀort to promote and facilitate medicinal
chemistry activities in such a direction.
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(103) Suaŕez, R. M.; Chevot, F.; Cavagnino, A.; Saettel, N.; Radvanyi,
F.; Piguel, S.; Bernard-Pierrot, I.; Stoven, V.; Legraverend, M.
Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and
biological evaluation. Eur. J. Med. Chem. 2013, 61, 2−25.
(104) Cui, J. J. Targeting receptor tyrosine kinase MET in cancer:
small molecule inhibitors and clinical progress. J. Med. Chem. 2014, 57,
4427−4453.
(105) Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L.
M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P.
Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol.
2011, 29, 1046−1051.
(106) Elisei, R.; Schlumberger, M. J.; Müller, S. P.; Schöffski, P.;
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